Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on November 5, 2020, covering events occurring on November 3, 2020. The Company is a Delaware corporation with its principal executive offices in Hanover, Maryland, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "PCSA."
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. However, it discloses specific transactional details related to a license agreement:
- License Payment: The Company paid $100,000 in cash to Elion Oncology, Inc.
- Equity Issuance: The Company issued 825,000 shares of its common stock to Elion Oncology, Inc.
- Future Obligations: The Company may be required to pay various milestone and royalty payments in the future pursuant to the License Agreement.
Material Changes
The primary material changes reported in this filing relate to corporate governance and strategic licensing:
- Board Appointment: Dr. Khalid Islam was appointed to the Board of Directors, effective November 3, 2020.
- Board Resignation: Patrick Lin resigned from the Board of Directors for personal reasons on November 3, 2020. He will continue to serve as Chief Business Strategy Officer.
- Licensing Milestone: On October 6, 2020, the Company satisfied contingencies related to an exclusive global license for PCS6422 acquired from Elion Oncology, Inc. on August 23, 2020.
Outlook, Risks, and Management Commentary
Management Commentary and Independence: Dr. Islam is a director and shareholder of Elion Oncology, Inc. Consequently, he is not considered independent under Nasdaq rules due to the License Agreement. He will receive compensation equivalent to other non-employee directors. There were no arrangements or understandings between Dr. Islam and other persons regarding his election.
Risks and Contingencies: The filing notes potential future financial obligations in the form of milestone and royalty payments to Elion Oncology, Inc. The resignation of Mr. Lin was explicitly stated as not resulting from any disagreement regarding the Company's operations, policies, or practices.
Key Facts for Investor Verification
- Verify the impact of the 825,000 share issuance to Elion Oncology, Inc. on existing shareholder dilution.
- Review the specific terms of the PCS6422 License Agreement to understand the magnitude of potential future milestone and royalty payments.
- Confirm the composition of the Board of Directors following the appointment of Dr. Islam and the resignation of Patrick Lin.
- Assess the strategic value of the PCS6422 asset given the Company's current cash position and development stage.